Legal & General Group Plc Raises Stock Holdings in Travere Therapeutics, Inc. $TVTX

Posted by Stanley Muller on Jun 1st, 2026

Legal & General Group Plc boosted its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 3.1% in the fourth quarter, HoldingsChannel reports. The firm owned 536,925 shares of the company’s stock after purchasing an additional 16,333 shares during the period. Legal & General Group Plc’s holdings in Travere Therapeutics were worth $20,516,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TVTX. Raymond James Financial Inc. purchased a new position in Travere Therapeutics in the second quarter valued at about $33,000. Torren Management LLC purchased a new position in Travere Therapeutics in the fourth quarter valued at about $38,000. Comerica Bank boosted its holdings in Travere Therapeutics by 77.5% in the fourth quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after purchasing an additional 492 shares during the last quarter. Garner Asset Management Corp purchased a new position in Travere Therapeutics in the fourth quarter valued at about $69,000. Finally, Headlands Technologies LLC purchased a new position in Travere Therapeutics in the second quarter valued at about $73,000.

Travere Therapeutics Price Performance

Shares of Travere Therapeutics stock opened at $47.18 on Monday. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 3.16. The business’s 50 day simple moving average is $37.94 and its 200-day simple moving average is $34.44. The stock has a market capitalization of $4.39 billion, a price-to-earnings ratio of -205.12 and a beta of 1.13. Travere Therapeutics, Inc. has a twelve month low of $13.88 and a twelve month high of $48.61.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The business had revenue of $127.20 million for the quarter, compared to analysts’ expectations of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The business’s quarterly revenue was up 55.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.47) EPS. Equities research analysts forecast that Travere Therapeutics, Inc. will post -0.26 earnings per share for the current year.

Analysts Set New Price Targets

TVTX has been the subject of a number of analyst reports. Weiss Ratings raised Travere Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 21st. Wall Street Zen downgraded Travere Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Canaccord Genuity Group increased their target price on Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Piper Sandler raised Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 target price on the stock in a report on Tuesday, April 14th. Finally, HC Wainwright increased their target price on Travere Therapeutics from $47.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Travere Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $47.83.

Read Our Latest Report on TVTX

Insider Buying and Selling at Travere Therapeutics

In other news, insider Elizabeth E. Reed sold 2,076 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total transaction of $91,240.20. Following the sale, the insider directly owned 105,211 shares in the company, valued at approximately $4,624,023.45. This represents a 1.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric M. Dube sold 22,500 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total value of $988,875.00. Following the sale, the chief executive officer owned 432,886 shares in the company, valued at $19,025,339.70. The trade was a 4.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 400,015 shares of company stock worth $15,895,428. Corporate insiders own 4.44% of the company’s stock.

Travere Therapeutics Company Profile

(Free Report)

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.